drugset / Trial / NCT00594984
Phase I/II Combination With Irinotecan- Erbitux
RandomizedParallel-groupDouble-blindTreatment
Summary
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)
Timeline
- Start
- 2008-05
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brivanib | Small molecule | 200 mg | Oral |
| Comparator | Brivanib | Small molecule | 400 mg | Oral |
| Comparator | Brivanib | Small molecule | 600 mg | Oral |
| Comparator | Brivanib | Small molecule | 800 mg | Oral |
| Comparator | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Comparator | Irinotecan | Small molecule | 350 mg/m2 | Intravenous |